慢性阻塞性肺病患者复合炎症标志物的预后值:基于MIMIC-IV数据库的回顾性队列研究
Xingxing Liu1, Yikun Guo2,3, Wensheng Qi1
1Guanganmen Hospital Affiliated to China Academy of Chinese Medical Sciences, Xicheng District, Beijing, China.
炎症标志物如SII,SIRI,PIV,NLR和PLR与慢性阻塞性肺病 (COPD) 患者的死亡率较高有关. 这些标记可以帮助预测COPD预后,并分层患者的风险.
科学领域:
- 肺部医学 肺部医学
- 炎症研究 炎症研究
- 生物标志物发现发现
背景情况:
- 慢性阻塞性肺病 (COPD) 是全球死亡的一个重要原因.
- 炎症是COPD病原和进展的一个关键因素.
- 确定可靠的COPD预后标志物对于患者管理至关重要.
研究的目的:
- 调查系统性免疫炎症指数 (SII),系统性炎症反应指数 (SIRI),泛免疫炎症值 (PIV),中性粒细胞与淋巴细胞的比率 (NLR),以及血小板与淋巴细胞的比率 (PLR) 与COPD患者的死亡率之间的关联.
- 评估这些复合炎症标志物对COPD预后的影响.
- 评估它们作为生物标志物的潜力,以评估COPD危急患者的风险分层和治疗.
主要方法:
- 利用了1234名COPD患者的MIMIC-IV数据库中的数据.
- 使用限制立方线 (RCS),COX比例危险回归,卡普兰-梅尔曲线和ROC分析.
- 根据基线炎症标志物水平,患者分为四组.
主要成果:
- 在COPD患者中,SII,SIRI,PLR,PIV和NLR显示出与住院死亡率的积极,非线性相关性.
- 这些复合炎症标志物被确定为在医院死亡的独立风险因素.
- 较高的SII,SIRI,PLR和PIV水平与显著降低的生存概率有关.
结论:
- 该研究表明,五种复合炎症标志物与COPD患者的死亡率之间存在显著的非线性相关性.
- 这些标志物作为COPD预后的风险因素,并可能是临床风险分层和管理的有价值的生物标志物.
- 进一步的研究可以探索它们在指导COPD关键病例治疗决策中的有用性.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
14:48Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
相关概念视频
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pneumonia III: Complications and Assessment
